Aptamer 学术简报 — therapeutic — 2026-09-09

自动生成 by RBTX Aptamer Tracker v0.1。 子主题 therapeutic：近 14 天 64 篇命中（aptamer 池 228 篇）。

评分公式：composite = 0.45×log(IF) + 0.35×log(cites_velocity) + 0.10×social + 0.10×recency_bonus；满分 100。

#1 [15.5] Folic acid-anchored liposomes in cancer therapy: a next-generation nanoplatform for precision drug delivery and tumor targeting.

Targeted drug delivery (TDD) has emerged as a potential strategy for cancer management by selectively delivering therapeutic agents directly to the targeted site. The current trends in TDD for cancer therapy, focus on the use of various ligands, such as hyaluronic acid, folic acid (FA), carbohydrates, peptides, antibodies, and aptamers to enhanc...

#2 [14.9] SOLiD-MaP: A Photoproximity Labeling Platform for Small Molecule Binding Site Mapping on RNA.

RNA-targeting small molecules are emerging as promising therapeutic modalities, but their development requires methods that define binding sites and evaluate RNA target selectivity. Existing approaches for detecting ligand-RNA interactions have provided powerful foundations, yet many rely on direct cross-linking or covalent-capture chemistries w...

#3 [14.1] Mammalian therapeutic riboswitches: Engineering and custom ligands.

Regulation with riboswitches, which induce or repress gene expression in response to a ligand, is moving from proof-of-concept studies to robust clinical-grade gene therapies. These initial stages in RNA-based precision medicine will soon benefit from the next generation of riboswitches, whose engineering results from the combination of deep lea...

#4 [13.0] Small-Molecule-Directed RNA Modification via Proximity-Driven Catalysis.

Selective chemical modification of RNA is essential for RNA functionalization, probing RNA structure-function relationships and developing RNA-targeted therapeutics. Existing chemical strategies often rely on guanine accessibility or multiple helper DNA strands, restricting their generality and biological applicability. Inspired by DNA-guided DM...

#5 [13.0] Multivariate-Activated DNA Logic Gate for Predicting Responses to Cisplatin-Based Chemotherapy

Abstract Cisplatin-based chemotherapy remains an attractive alternative for controlling advanced cancers. However, a subset of cancer patients exhibits resistance to cisplatin. Accurate and early prediction of individual responses to cisplatin treatment is critical to personalized medicine guidance. The development of an effective method to pred...

#6 [12.9] Co-Assembled Mirror-Image DNA Nanostructure for Effective Alleviation of Acute Kidney Injury.

The high demand for acute kidney injury (AKI) therapy calls for the development of new therapeutics for renal management. Oxidative stress, coupled with excessive inflammation, is the main pathological mechanism for AKI. Specifically, complement component 5a (C5a) exacerbates the vicious cycle between oxidative stress and inflammatory responses....

#7 [12.8] Competitive SELEX Strategy for High-Affinity Aptamer Isolation and Enhanced Biosensing.

Aptamers, with their high specificity and affinity, are invaluable for diagnostics and therapeutics. However, conventional SELEX (Systematic Evolution of Ligands by Exponential Enrichment) often favors abundant low-affinity sequences, limiting the isolation of rare, high-affinity candidates. To overcome this challenge, we introduce a competitive...

#8 [12.6] Aptamer-Functionalized Liposomes for Targeted Delivery of Anticancer Drugs in Lung Cancer

Aptamer-functionalized liposomes are a promising strategy to improve the selectivity of anticancer therapies. AT11-L2 is a G-quadruplex (G4)-forming aptamer with high affinity for nucleolin (NCL), which is overexpressed at the surface of non-small cell lung cancer (NSCLC) cells. Here, we developed AT11-L2-functionalized liposomes loaded with dox...

#9 [12.6] T cell-anchored ATP-responsive doxorubicin-loaded dual aptamer DNA nanodevice for enhanced solid tumor therapy

#10 [12.5] A Receptor-Mediated Endolysosomal Recycling Chimera Enables Catalytic TNF-α Degradation for Sustained Treatment of Mucosal Inflammation.

Mucosal inflammatory disorders such as dry eye disease (DED) and inflammatory bowel disease (IBD), driven by TNF-α-mediated immune-epithelial crosstalk, remain therapeutically challenging. Conventional inhibitors often suffer from poor mucosal permeability and transient efficacy with 1:1 binding. Although extracellular protein degradation (eTPD)...

Methodology